SCHEMBL3889255

SCHEMBL3889255

CC(C)(C)OC(=O)NC1CC(NC(=O)OCc2ccccc2)CCC1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
GAA P10253 1/20 0.54
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM1A O60341 2/20 0.51
MAOB P27338 2/20 0.51
CPB1 P15086 2/20 0.50
TLR4 O00206 1/20 0.47
EPHX1 P07099 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ACHE P22303 2/20 0.46
CCR2 P41597 1/20 0.46
SYK P43405 1/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSK P43235 1/20 0.45
DRD2 P14416 1/20 0.44
DPP4 P27487 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24226875 1.00 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL23871744 1.00 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL18544185 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL3892622 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL18544213 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL18544475 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL18544476 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL23871461 0.91 ALDH1A1 (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL22241957 0.91 KMT2A (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1
SCHEMBL22241959 0.91 KMT2A (0.54) ALDH1A1GAATSHRKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572813-B2 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-11 US disclosed
US-20060135502-A1 Cyclic derivatives as modulators of chemokine receptor activity CHERNEY ROBERT 2006-06-22 US disclosed
US-7045521-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2006-05-16 US disclosed
US-20040110736-A1 Cyclic derivatives as modulators of chemokine receptor activity CHERNEY ROBERT (US) 2004-06-10 US disclosed
US-6706712-B2 RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-16 US disclosed
US-20030004151-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110736-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 ALDH1A1 1095/4885GAA 4566/4885TSHR 1088/4885
US-20030004151-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 ALDH1A1 1095/4885GAA 4566/4885TSHR 1088/4885
US-20060135502-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCL2, CCR1 ALDH1A1 1345/4885GAA 4561/4885TSHR 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.